[Galsulfase (Naglazyme) for the treatment of mucopolysaccharidosis type VI]

Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32010000705
Authors' objectives:

To assess the efficacy, safety and efficiency of galsulfase compared to any other treatment alternatives, including placebo, in the treatment of patients with MPS VI.

Authors' recommendations: Galsulfase is the only pharmacological treatment approved for patients with MPS VI. Its efficacy has been proven in the short and mid-term when compared to placebo in terms of improvements in the distance walked in the 12 minute walk test. The clinical relevance of the results is unknown.
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Humans
  • N-Acetylgalactosamine-4-Sulfatase
  • Recombinant Proteins
  • Mucopolysaccharidoses
Organisation Name: Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address: Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email: direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright: Catalan Agency for Health Technology Assessment and Research (CAHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.